System administration of a drug for use in the treatment or diagnosis of neurological disorders

VLP derived from a human polyomavirus comprising a drug for use in a method of treatment by therapy or diagnostic method in vivo of a neurological disorder of the central nervous system in which the neurological disorder is selected from the group consisting of stroke, addiction alcohol, Alzheimer's disease, anxiety, hyperactivity disorder attention deficit disorder, bipolar disorder, cancer pain, cerebral ischemia, cervical dystonia, chorea associated with Huntington's disease, chronic pain, severe chronic pain, cognitive impairment, cortical myoclonus , depression, diabetic neuropathic pain, emotional lability, epilepsy, excessive sleepiness associated with narcolepsy, fragile X syndrome, Friedreich's ataxia, insomnia, Lennox Gastaut syndrome, depression and higher anxiety disorders, manic episodes associated with bipolar disorder, impaired memory, migraine, mild cognitive impairment, moderate to severe pain in fermedad of motor neurons, multiple sclerosis, musculoskeletal pain, narcolepsy, neuropathic pain, nicotine dependence, obsessive compulsive disorder, osteoarthritis pain, pain, Parkinson's disease, pediatric drooling, postoperative pain, premenstrual dysphoric disorder, psychosis, seizures, partial complex refractory, schizophrenia, seizures, sleep disorder, smoking cessation, spasticity, injury to the spine, polyneuropathy transthyretin familial amyloid, traumatic brain injury, vertigo, amyotrophic lateral sclerosis, spinocerebellar ataxia type I, extrapyramidal and movement disorders, attack transient ischemic attack (TIA), progressive multifocal leukoencephalopathy (PML), dementia, as Alzheimer's disease, vascular dementia, frontotemporal dementia, semantic dementia and Lewy body dementia.